Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cholinergic Antagonists: Therapeutic Uses

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...

Cholinergic Antagonists: Pharmacological Actions

Cholinergic Antagonists: Pharmacological Actions

Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Cholinergic Antagonists: Pharmacokinetics

Cholinergic Antagonists: Pharmacokinetics

Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative impact of mental and cardiovascular comorbidities on adverse outcomes in people with MS.

Journal of the neurological sciences·2026

Same author

Fatigue prevalence, interactions with associated symptoms and longitudinal changes in those with multiple sclerosis: Insights from the TONiC study.

Journal of the neurological sciences·2026

Same author

Employment status in people with multiple sclerosis: Profile, dynamic changes and determinants over time.

Multiple sclerosis and related disorders·2025

Same author

EQ-5D-5L in Multiple Sclerosis: Estimated Utility Values, Minimal (Clinically) Important Changes, and Direct and Indirect Influences Over Time.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025

Same author

Fatigue in amyotrophic lateral sclerosis/motor neuron disease: prevalence, influences and trajectories.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025

Same author

Patient reported outcome measures require scale metrification and quantified precision: evidence from the assessment of breathlessness in people with ALS/MND.

Amyotrophic lateral sclerosis & frontotemporal degeneration·2025

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

Anticholinergics for urinary symptoms in multiple sclerosis.

Richard S Nicholas¹, Tim Friede, Sally Hollis

¹West London Neurosciences Centre, Charing Cross Hospital, Fulham Palace Road, London, UK, W6 8RF. richard.nicholas@btinternet.com

The Cochrane Database of Systematic Reviews

|January 23, 2009

Summary

Anticholinergic drugs show limited efficacy for urinary symptoms in Multiple Sclerosis (MS). Side effects were common, and evidence does not support their routine use in MS patients.

More Related Videos

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

Related Experiment Videos

Last Updated: Jun 26, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology

Published on: August 18, 2014

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

The Use of Cystometry in Small Rodents: A Study of Bladder Chemosensation

Published on: August 21, 2012

Area of Science:

Neurology
Pharmacology

Background:

Multiple Sclerosis (MS) is a leading cause of neurological disability in young adults.
Urinary symptoms affect approximately 68% of MS patients, with diverse and evolving causes.

Purpose of the Study:

To evaluate the efficacy, tolerability, and safety of anticholinergic medications for managing urinary dysfunction in individuals with MS.

Main Methods:

Systematic review of randomized and cross-over trials comparing anticholinergics to placebo or other treatments.
Searched multiple databases including Cochrane, MEDLINE, and EMBASE from inception to January 2008.
Included three trials involving Methantheline Bromide, Flavoxate Chloride, Meladrazine Tartrate, Oxybutynin, Propantheline, and Atropine.

Main Results:

Limited statistically significant benefits were observed for some anticholinergics in specific urinary symptoms.
Frequent side effects were reported across all treatments evaluated.
One trial showed no significant efficacy difference between oral Oxybutynin and intravesical Atropine, with Atropine favoring side effect profiles and quality of life.

Conclusions:

The current evidence base is insufficient to recommend the use of anticholinergic agents for urinary symptoms in Multiple Sclerosis.
Further research is needed to clarify the role and optimal use of these agents in MS management.